Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted)NEW YORK, ...

PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...

Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, Prime Standard) (“Formycon” or “the Company”) today provided an update on key developments across various biosimilar projects and invites ...

This was followed by Merck & Co’s Keytruda (pembrolizumab) and a gang of rival PD-L/PD-L1 checkpoint inhibitors, which have set new standards in cancer care in many different forms of the disease.

PLANEGG-MARTINSRIED I Germany I 17, 2025 I The Executive Board of Formycon AG (FSE: FYB, Prime Standard) (“Company”) has decided today to prematurely ...

Gilead (GILD) stock won an upgrade from Deutsche Bank on HIV treatment boost, while Merck (MRK) stock received a downgrade on ...

Keytruda’s approval by the EMA comes on the back of the phase III KEYNOTE-054 trial, which showed that the drug reduced the risk of disease recurrence or death by 44% compared to placebo.

The company is currently conducting a pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) investigating Cylembio in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab ...

The company is currently conducting several pivotal clinical trials evaluating Cylembio in combination with Merck's KEYTRUDA® for treating advanced melanoma and other solid tumors. Enrollment for ...

Merck (MRK) stock in focus as anti-cancer agent Welireg is approved in the EU for kidney tumor conditions, VHL disease and ...